Coagulant Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
2ndary - Private
- Investors
-
17
Coagulant Therapeutics General Information
Description
Developer of hemostatic medicines designed to treat acute bleeding, an unmet medical need. The company's drugs offer an optimized, proprietary rFVIIa molecule, termed CT-001, for the prevention and treatment of acute bleeding and other coagulation cascade-related diseases and leverages expertise in biologics to develop novel therapeutics targeted to treat adjacencies, enabling doctors to treat traumatic injury and save the lives of many young people.
Contact Information
Website
www.coagulanttherapeutics.comCorporate Office
- 2630 Bancroft Way
- Berkeley, CA 94704
- United States
Corporate Office
- 2630 Bancroft Way
- Berkeley, CA 94704
- United States
Coagulant Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Secondary Transaction - Private | Completed | Pre-Clinical Trials | ||||
| 4. Early Stage VC (Series A2) | 22-Apr-2021 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC | 21-Jan-2020 | Completed | Startup | |||
| 2. Early Stage VC (Series A1) | 08-Jul-2019 | $21M | $21M | Completed | Startup | |
| 1. Accelerator/Incubator | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Coagulant Therapeutics Patents
Coagulant Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023229091-A1 | Camelid antibodies against activated protein c and uses thereof | Pending | 04-Mar-2022 | ||
| EP-4486381-A2 | Camelid antibodies against activated protein c and uses thereof | Pending | 04-Mar-2022 | ||
| EP-4486381-A4 | Camelid antibodies against activated protein c and uses thereof | Pending | 04-Mar-2022 | ||
| WO-2023168429-A2 | Camelid antibodies against activated protein c and uses thereof | Inactive | 04-Mar-2022 | ||
| WO-2023168429-A3 | Camelid antibodies against activated protein c and uses thereof | Inactive | 04-Mar-2022 | C07K16/40 |
Coagulant Therapeutics Signals
Coagulant Therapeutics Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aventures Capital Management | Venture Capital | Minority | ||
| Colopl Next | Corporate Venture Capital | Minority | ||
| DT & Investment | Corporate Venture Capital | Minority | ||
| G.N. Tech Venture Capital | Venture Capital | Minority | ||
| Hana Financial Group | Holding Company | Minority |
Coagulant Therapeutics FAQs
-
When was Coagulant Therapeutics founded?
Coagulant Therapeutics was founded in 2019.
-
Where is Coagulant Therapeutics headquartered?
Coagulant Therapeutics is headquartered in Berkeley, CA.
-
What is the size of Coagulant Therapeutics?
Coagulant Therapeutics has 4 total employees.
-
What industry is Coagulant Therapeutics in?
Coagulant Therapeutics’s primary industry is Drug Discovery.
-
Is Coagulant Therapeutics a private or public company?
Coagulant Therapeutics is a Private company.
-
What is Coagulant Therapeutics’s current revenue?
The current revenue for Coagulant Therapeutics is .
-
How much funding has Coagulant Therapeutics raised over time?
Coagulant Therapeutics has raised $38M.
-
Who are Coagulant Therapeutics’s investors?
Aventures Capital Management, Colopl Next, DT & Investment, G.N. Tech Venture Capital, and Hana Financial Group are 5 of 17 investors who have invested in Coagulant Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process